Amir Nashat bought $2.0M of CAMP4 THERAPEUTICS (CAMP)
Executed Sep 11 2025, disclosed Sep 11 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Sep 11 2025), the stock returned +44.7% (delay-adjusted); from the execution session (Sep 11 2025), +44.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Amir Nashat (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in CAMP4 THERAPEUTICS CORPORATION (CAMP). Across 1 priced purchase filing, the average 21-session return was +44.7% from execution and +44.7% from disclosure (delay-adjusted; derived). The largest single filing was $2.0M of CAMP (1,307,189 sh across 2 lots, as filed), executed Sep 11 2025.
Healthcare · Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→